Therapeutics News and Research

RSS

Nuon study confirms potential utility of tranilast as uricosuric agent

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that results from clinical and preclinical studies demonstrating the ability of tranilast to reduce serum uric acid levels and monosodium urate crystal-induced inflammation - two important risk factors for gout - were presented at The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology in Rome, Italy, June 16-19, 2010.

22 Jun 2010

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Probactive Biotech, Inc., a Garden Grove, California-based corporation, has entered into an agreement with Dalat Nuclear Research Institute to co-develop a number of cancer drugs, utilizing combinations of antitumor antibodies and antitumor radioactive compounds. Antitumor antibodies have the ability to take antitumor compounds directly to the tumor sites within the body.

22 Jun 2010

Ensemble Discovery announces name change to Ensemble Therapeutics Corporation

Ensemble Discovery today announced that it will begin operating as Ensemble Therapeutics Corporation to reflect the Company's progress and emerging pipeline by applying its macrocycle drug platform to develop novel therapeutics. The new name, Ensemble Therapeutics, conveys the company's leadership and advancement in developing novel macrocycle drug compounds that are small molecules with expanded therapeutic properties of large molecule biological drugs.

22 Jun 2010

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has received its first purchase order for DAVANAT from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Pro-Pharmaceuticals has received a purchase order for $200,000 which will be the upfront payment for this first shipment of DAVANAT.

22 Jun 2010

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.

22 Jun 2010

Novel MC4R agonist exhibits potential as new treatment for obesity, diabetes

Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, today announced a study of obese primates treated with RM-493 showing a reversal of obesity and insulin resistance, and improvement in both heart rate and blood pressure. RM-493 is a novel peptide agonist targeting the melanocortin 4 receptor (MC4R) that is a clinical candidate for the treatment of obesity and diabetes.

22 Jun 2010

TransGenRx to produce protein-based therapeutics to support Esperion's research on HDL therapies

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.

22 Jun 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. One of the grants supports the first large, multi-center, randomized clinical trial to compare outcomes in heart surgery patients who receive transfusions of red blood cells that have been stored for shorter or longer amounts of time.

22 Jun 2010

Incline acquires IONSYS, announces $43 million Series A financing

Incline Therapeutics, Inc., a privately-held, hospital-focused specialty pharmaceutical company, announced today that it has entered into an agreement to acquire the rights to IONSYS™ (fentanyl iontophoretic transdermal system) from ALZA Corporation and completed a $43 million Series A financing.

22 Jun 2010

Cadence Pharmaceuticals to acquire Incline Therapeutics

Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it has signed an agreement providing Cadence with an exclusive option to acquire Incline Therapeutics, Inc., a privately held specialty pharmaceutical company.

22 Jun 2010

First StemSource Cell Bank in U.S. open

BioLife Cell Bank, LLC has opened the first U.S. StemSource® Cell Bank, which offers patients a way to safely and affordably store their own adipose (fat) tissue or their own naturally occurring adipose (fat) tissue-derived stem and regenerative cells. This gives patients and physicians easy, multi-use access to cells and tissue for future approved or allowed reconstructive fat grafting or augmentation procedures using the patients' own cells and/or tissue.

21 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

Dyax signs partnership agreement with Sigma-Tau to develop and commercialize subcutaneous DX-88

Dyax Corp. and Defiante Farmaceutica S.A., a subsidiary of the pharmaceutical company Sigma-Tau SpA, announced today a strategic partnership to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema and other therapeutic indications throughout Europe, North Africa, Middle East and Russia.

21 Jun 2010

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

Cerenis Therapeutics SA, a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.

21 Jun 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

21 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

ExonHit Therapeutics informs shareholders about Highmark's intention to discontinue coverage of PathFinderTG

ExonHit Therapeutics today informs its shareholders that it learned on June 16, 2010 from RedPath Integrated Pathology that Highmark (the Medicare reimbursement regional antenna for the states of Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania) announced its intention to discontinue coverage of PathFinderTG - Pancreatic cancer, contingent to a complementary assessment of the utility of the product.

19 Jun 2010

Carolinas recipients for 2010 Ernst & Young Entrepreneur Of The Year award announced

Ernst & Young LLP is pleased to announce the winners of the Ernst & Young Entrepreneur Of The Year award in the Carolinas. This group of leading entrepreneurs was selected by an independent judging panel made up of regional business, academic and community leaders. The winners were revealed at a gala event on June 17, 2010 at The Westin Charlotte hotel in Charlotte, North Carolina.

19 Jun 2010

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

The Cancer Prevention and Research Institute of Texas today awarded $142 million in grants to fund innovative cancer research and prevention programs across the state. Today's announcement caps the first year of the Institute's ten year mission. Together with matching funds committed by grant recipients, more than $300 million has been invested this year in Texas' extraordinary endeavor to change the face of cancer.

19 Jun 2010

Therapeutics News and Research

Nuon study confirms potential utility of tranilast as uricosuric agent

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Ensemble Discovery announces name change to Ensemble Therapeutics Corporation

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Novel MC4R agonist exhibits potential as new treatment for obesity, diabetes

TransGenRx to produce protein-based therapeutics to support Esperion's research on HDL therapies

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

Incline acquires IONSYS, announces $43 million Series A financing

Cadence Pharmaceuticals to acquire Incline Therapeutics

First StemSource Cell Bank in U.S. open

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Dyax signs partnership agreement with Sigma-Tau to develop and commercialize subcutaneous DX-88

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

ExonHit Therapeutics informs shareholders about Highmark's intention to discontinue coverage of PathFinderTG

Carolinas recipients for 2010 Ernst & Young Entrepreneur Of The Year award announced

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News